Kura Oncology Stock Revenue
| KURA Stock | USD 17.56 0.12 0.68% |
Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.
| Last Reported | Projected for Next Year |
Kura | Revenue |
Kura Oncology Company Revenue Analysis
Kura Oncology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Kura
Projected quarterly revenue analysis of Kura Oncology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Kura Oncology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Kura Oncology's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Kura Cost Of Revenue
Cost Of Revenue |
|
Based on the latest financial disclosure, Kura Oncology reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Kura Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in revenue category among its peers.
Kura Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kura Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kura Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Kura Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Kura Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kura Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kura Oncology's value.| Shares | Armistice Capital, Llc | 2024-06-30 | 2.4 M | Foresite Capital Management Iv, Llc | 2024-06-30 | 1.8 M | Artal Group S A | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Commodore Capital Lp | 2024-06-30 | 1.6 M | Franklin Resources Inc | 2024-06-30 | 1.6 M | Tcg Crossover Management, Llc | 2024-06-30 | 1.4 M | Assenagon Asset Management Sa | 2024-09-30 | 1.1 M | Citadel Advisors Llc | 2024-06-30 | 1 M | Suvretta Capital Management, Llc | 2024-06-30 | 7.1 M | Blackrock Inc | 2024-06-30 | 7 M |
Kura Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 936.2 M | ||||
| Shares Outstanding | 77.76 M | ||||
| Shares Owned By Insiders | 1.05 % | ||||
| Shares Owned By Institutions | 98.95 % | ||||
| Number Of Shares Shorted | 9.29 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 3.24 X | ||||
| EBITDA | (164.96 M) | ||||
| Net Income | (152.63 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 17.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.45 X | ||||
| Cash Flow From Operations | (124.82 M) | ||||
| Short Ratio | 18.16 X | ||||
| Earnings Per Share | (2.35) X | ||||
| Target Price | 29.57 | ||||
| Number Of Employees | 142 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 1.37 B | ||||
| Total Asset | 448.94 M | ||||
| Retained Earnings | (721.44 M) | ||||
| Working Capital | 397.22 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 448.94 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.